No profile data available.
Acadia Pharmaceuticals Inc. (ACAD) is a healthcare company in the brain and nerve treatment drugs industry, based in San Diego, United States, with about 653 full-time employees.
It reported revenue of $957.80 million for fiscal year 2024, up 31.8% from fiscal year 2023, and net income of $226.45 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $278.63 million, up 11.3% from a year before. Its market capitalization was $4.49 billion as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of December 4, 2025.
, a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
Acadia Pharmaceuticals reported $957.80 million in revenue for fiscal year 2024, up 31.8% from $726.44 million in fiscal year 2023. In Q3 2025 revenue was $278.63 million.
$4.49 billion as of December 4, 2025.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Scholar Rock Holding Corporation (SRRK), Praxis Precision Medicines, Inc. (PRAX), Dianthus Therapeutics, Inc. (DNTH), Edgewise Therapeutics, Inc. (EWTX).